Article
Semaglutide offers new route to cardiovascular risk reduction
Rating:
0.0
Views:
44
Likes:
1
Library:
1
In people with cardiovascular disease (without diabetes) and overweight or obesity, the GLP-1 receptor agonist semaglutide significantly reduced the risk of major cardiovascular events.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value